<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the nonacute management of ST-elevation myocardial infarction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the nonacute management of ST-elevation myocardial infarction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the nonacute management of ST-elevation myocardial infarction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Guy S Reeder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold L Kennedy, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James Hoekstra, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Once the diagnosis of an acute ST-elevation myocardial infarction (STEMI) is made, the early management of the patient involves the simultaneous achievement of several goals including relief of ischemic pain, assessment of the hemodynamic state and correction of abnormalities that are present, initiation of reperfusion therapy with primary percutaneous coronary intervention or fibrinolysis, and initiation of antithrombotic therapy. (See  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a> and  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a>.)</p><p>These early diagnostic and therapeutic interventions are followed by the initiation of short- and long-term interventions aimed at improving in-hospital and long-term outcomes. This topic will summarize the management of patients with acute STEMI in the hours and days following the very early decision-making period. (See  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a>.)</p><p>The management of the patient with a non-ST-elevation or non-Q-wave MI or with a complication of an acute MI (eg, cardiogenic shock, mitral regurgitation, ventricular septal defect) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/83.html" rel="external">"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/63.html" rel="external">"Acute myocardial infarction: Mechanical complications"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">FURTHER MEDICAL THERAPY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> and a platelet P2Y<sub>12</sub> receptor blocker are usually given as soon as the diagnosis of acute STEMI is made. (See  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction", section on 'Routine medical therapy'</a>.)</p><p>Early initiation of the following therapies may be of benefit in patients hospitalized with STEMI. Many of them are useful long term. (See <a class="local">'Preparing for discharge'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Oral beta blockers</span><span class="headingEndMark"> — </span>An oral cardioselective beta blocker should be continued or begun if the patient has not received early, oral beta blocker therapy. Patients who did not receive a beta blocker during the first 24 hours because of early contraindications should be reevaluated for beta blocker candidacy.</p><p>Most patients are continued on an oral beta blocker indefinitely. The efficacy of beta blocker therapy is related in part to the degree of heart rate slowing. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a>.)</p><p>The concomitant use of beta blockers and angiotensin inhibitors is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy", section on 'Contraindications'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Nitrates</span><span class="headingEndMark"> — </span>Nitrates can be useful during the first 24 to 48 hours in patients with recurrent ischemia, hypertension, or heart failure (HF). However, nitrates should be avoided in patients with a right ventricular MI in whom the reduction in preload can lower the cardiac output. (See  <a class="medical medical_review" href="/z/d/html/75.html" rel="external">"Right ventricular myocardial infarction", section on 'Optimization of right ventricular preload'</a>.)</p><p>Nitrate therapy after 48 hours is useful for the treatment of recurrent ischemia or HF as long as it does not preclude adequate therapy with agents proven to reduce mortality, such as beta blockers or angiotensin converting enzyme (ACE) inhibitors. (See  <a class="medical medical_review" href="/z/d/html/64.html" rel="external">"Nitrates in the management of acute coronary syndrome"</a>.)</p><p>Nitrates used for this purpose include <a class="drug drug_general" data-topicid="8580" href="/z/d/drug information/8580.html" rel="external">isosorbide dinitrate</a>, <a class="drug drug_general" data-topicid="8581" href="/z/d/drug information/8581.html" rel="external">isosorbide mononitrate</a>, or a transdermal <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> patch. (See  <a class="medical medical_review" href="/z/d/html/1549.html" rel="external">"Nitrates in the management of chronic coronary syndrome", section on 'Nitrate tolerance'</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Phosphodiesterase-5 inhibitors</span><span class="headingEndMark"> — </span>The phosphodiesterase-5 inhibitors (<a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="10172" href="/z/d/drug information/10172.html" rel="external">vardenafil</a>, and <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>) are contraindicated in patients taking nitrates because of the potential for exaggerated vasodilation and hypotension and an increased risk of MI or death. (See  <a class="medical medical_review" href="/z/d/html/1541.html" rel="external">"Sexual activity in patients with cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Statin therapy</span><span class="headingEndMark"> — </span>Intensive statin therapy should be initiated as early as possible in all patients with STEMI [<a href="#rid1">1-5</a>]. (See  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome", section on 'Inpatient management'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Calcium channel blockers</span><span class="headingEndMark"> — </span>Calcium channel blockers primarily serve as adjunctive therapy in patients with ongoing or recurrent symptoms of ischemia despite optimal therapy with beta blockers (with or without nitrates), in patients who are unable to tolerate adequate doses of one or both of these agents, or in patients with rapid atrial fibrillation when beta blockers are contraindicated. </p><p>No calcium channel blocker has been shown to reduce mortality in acute STEMI, and in certain patients they may be harmful, such as those with evidence of HF, left ventricular (LV) dysfunction, or atrioventricular block.</p><p>When a calcium channel blocker is used for the indications above, only <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> are recommended in patients with STEMI. Immediate release <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> is contraindicated because of the reflex sympathetic activation, tachycardia, and hypotension associated with its use. (See  <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers", section on 'Possible increased mortality after acute myocardial infarction'</a>.)</p><p>The second generation dihydropyridine calcium channel blockers, <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> and <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">felodipine</a>, appear to be safe in other forms of cardiovascular disease. Extrapolation from the results of these trials does not necessarily confirm that amlodipine or felodipine are safe in patients with an acute STEMI. Nonetheless, these agents, especially amlodipine, are often used when hypertension is not adequately controlled by other therapy of proven benefit (beta blockers and ACE inhibitors).</p><p class="headingAnchor" id="H8"><span class="h2">In-hospital glycemic control</span><span class="headingEndMark"> — </span>The correction of hyperglycemia has become standard care for hospitalized patients, including those with acute MI. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Venous thromboembolism prophylaxis</span><span class="headingEndMark"> — </span>Prophylaxis for venous thromboembolism should be considered in medical patients who are immobilized. (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p>However, many patients with STEMI are now ambulatory within 24 hours, particularly if they have received reperfusion therapy and have had uncomplicated courses. These patients do not require such prophylaxis. (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults", section on 'Summary and recommendations'</a>.)</p><p>We suggest that in patients with uncomplicated STEMI, who will be at bed rest for less than 24 hours, venous thromboembolism prophylaxis is not necessary (unless indicated for some other reason). For STEMI patients in whom bed rest is anticipated for more than 24 hours and for whom anticoagulation is no longer required as part of the management of their acute coronary syndrome, we suggest low-dose <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (5000 units every 8 to 12 hours), low molecular weight heparin (eg, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> 40 mg/day), or <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> 2.5 mg/day, all given subcutaneously, until the patient is ambulatory.</p><p class="headingAnchor" id="H10"><span class="h2">Red cell transfusion</span><span class="headingEndMark"> — </span>As in the acute setting, red blood cell transfusion is generally reserved for severe or symptomatic anemia, such as hemoglobin &lt;8 g/dL or hemoglobin 8 to 10 g/dL with hemodynamic instability or ongoing ischemia. Clinical judgment is required to determine if transfusion is likely to improve oxygen delivery or if there are other reasons to consider transfusion such as active bleeding or trauma. In deciding when to transfuse, individual patient characteristics such as the rate of blood loss and severity of myocardial ischemia need to be taken into account.</p><p>The rationale for using a restrictive transfusion strategy (limiting transfusions, transfusing for a lower rather than a higher hemoglobin level) includes avoiding risks of transfusion reactions or transfusion-transmitted infection and limiting burdens and costs while using evidence-based thresholds for optimal outcomes. While anemia correlates with worse outcomes, this is likely to be an association rather than causation. (See  <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Overview of our approach'</a>.)</p><p>Supporting data for the thresholds used in acute MI are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Acute MI'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Gastrointestinal prophylaxis</span><span class="headingEndMark"> — </span>Patients with ACS who develop gastrointestinal bleeding after percutaneous coronary intervention have significantly worse outcomes. (See  <a class="medical medical_review" href="/z/d/html/13605.html" rel="external">"Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention", section on 'Outcomes'</a>.)</p><p>The discussion of the primary prevention of gastrointestinal bleeding is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13605.html" rel="external">"Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">RECURRENT CHEST PAIN</span><span class="headingEndMark"> — </span>Recurrent chest pain after acute STEMI is typically caused by either recurrent ischemia and reinfarction or by postinfarction pericarditis. Usually, recurrent chest pain within the first 12 hours of onset of MI is considered to be related to the original infarct and not evidence of reinfarction. Pericarditis is probably not responsible for significant chest discomfort in the first 24 hours.</p><p>A somewhat separate issue, chest pain or silent ischemia on stress testing before or soon after discharge, is discussed below. (See <a class="local">'Stress testing'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h2">Recurrent ischemia and reinfarction</span><span class="headingEndMark"> — </span>Among patients with an STEMI who have undergone apparently successful fibrinolysis by clinical criteria, early recurrence of ischemia (threatened reocclusion) has been observed in 20 to 30 percent of patients [<a href="#rid6">6,7</a>], thrombotic coronary reocclusion in 5 to 15 percent [<a href="#rid8">8-10</a>], and reinfarction in 3 to 5 percent [<a href="#rid11">11-14</a>]. Among patients treated with fibrinolysis, reinfarction occurs at a median of two to four days after therapy and is associated with increases in in-hospital and 30-day mortality compared to those patients without reinfarction [<a href="#rid11">11,13</a>]. As many patients who have undergone fibrinolysis are routinely referred for percutaneous coronary intervention (PCI), the frequency of recurrent ischemia after fibrinolysis is decreasing. (See  <a class="medical medical_review" href="/z/d/html/53.html" rel="external">"Percutaneous coronary intervention after fibrinolysis for acute ST-elevation myocardial infarction"</a>.)</p><p>Recurrent ischemia or reinfarction after primary PCI represents ischemia in a coronary distribution not revascularized or possible stent thrombosis.</p><p class="headingAnchor" id="H15"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>Within the first 18 hours of the initial MI, a recurrent elevation in cardiac biomarkers alone should <strong>not</strong> be relied upon to diagnose reinfarction, but should be accompanied by recurrent ST segment elevation on electrocardiogram and at least one other supporting criterion (such as recurrent chest pain or hemodynamic decompensation). For patients more than 18 hours from the initial MI, a biomarker rise and at least one additional criterion are sufficient for the diagnosis.</p><p class="headingAnchor" id="H16"><span class="h3">Management</span><span class="headingEndMark"> — </span>Initial medical management of recurrent ischemia after STEMI should include escalation of therapy with beta blockers and nitrates to decrease myocardial oxygen demand and reduce ischemia. Intravenous anticoagulation should be initiated if it is not already being administered. For patients with hemodynamic instability, poor LV function, or a large area of myocardium at risk, insertion of an intraaortic balloon pump should also be considered.</p><p>PCI is the treatment of choice for patients with recurrent ischemia. Patients with recurrent ST elevation can also be treated or retreated with fibrinolytic therapy. However, an invasive strategy of angiography and revascularization is usually preferred. Patients should <strong>not</strong> be retreated with streptokinase. (See  <a class="medical medical_review" href="/z/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Infarction pericarditis</span><span class="headingEndMark"> — </span>Acute pericarditis, generally defined as a pericardial friction rub with or without chest discomfort, may complicate the course of an acute MI. Chest pain is typically pleuritic. Pain in one or both trapezius ridges is especially consistent with the diagnosis. The evaluation and management of this complication are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4937.html" rel="external">"Pericardial complications of myocardial infarction", section on 'Peri-infarction pericarditis'</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">PREPARING FOR DISCHARGE</span><span class="headingEndMark"> — </span>Activity level in-hospital is determined by clinical status; most uncomplicated patients will be able to ambulate when the risk of bleeding from the arterial puncture site is low. Prior to discharge, the patient should undergo risk stratification, including noninvasive measurement of resting LV function and possibly exercise testing. (See <a class="local">'Recurrent ischemia and reinfarction'</a> above.)</p><p>Other components of predischarge planning include counseling about changes in behavior/lifestyle (smoking cessation, dietary improvement, and cardiac rehabilitation) and appropriate medical therapy to reduce the risk for further ischemic episodes. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Early discharge after an uncomplicated MI</span><span class="headingEndMark"> — </span>Early discharge (within three to five days) of a patient undergoing reperfusion who has had an uncomplicated acute STEMI (no angina or evidence of ischemia, bleeding, HF, or arrhythmia 72 hours after the event) is considered safe [<a href="#rid15">15-18</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Risk stratification</span><span class="headingEndMark"> — </span>Late risk stratification is performed before or sometimes after discharge. The main components are measurement of the LV ejection fraction (LVEF) and, in many patients, stress testing to detect possible residual ischemia. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction"</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Evaluation of left ventricular function</span><span class="headingEndMark"> — </span>Assessment of resting LV function is an important part of risk stratification in patients with acute MI and was given a strong recommendation in the 2013 American College of Cardiology Foundation/American Heart Association guideline for the management of STEMI [<a href="#rid3">3,4</a>]. Patients with LV systolic dysfunction have increased mortality at six months and one year  (<a class="graphic graphic_figure graphicRef75743 graphicRef68071" href="/z/d/graphic/75743.html" rel="external">figure 1A-B</a>) [<a href="#rid19">19,20</a>]. The increase in mortality is most pronounced in the 8 to 10 percent of patients with an LVEF ≤30 percent [<a href="#rid19">19,20</a>].</p><p>In the absence of a specific indication (eg, HF or suspected mechanical complication), the LVEF is usually measured before discharge. However, early measurements of LVEF may be misleading, since improvement in LVEF, beginning within three days and largely complete by 14 days, is common in patients who are reperfused, a presumed reflection, at least in part, of recovery from myocardial stunning [<a href="#rid21">21,22</a>].</p><p>Multiple imaging techniques for assessing LV function are available and each has equivalent prognostic value in the post-MI patient. In general, echocardiography should be used for routine assessment of LVEF after acute MI. It has the added advantage of detecting other factors that can be associated with a worse prognosis such as diastolic dysfunction, concurrent right ventricular dysfunction, left atrial enlargement, mitral regurgitation, and LV thrombus [<a href="#rid23">23-27</a>]. (See  <a class="medical medical_review" href="/z/d/html/79.html" rel="external">"Role of echocardiography in acute myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/90.html" rel="external">"Left ventricular thrombus after acute myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/102361.html" rel="external">"Chronic secondary mitral regurgitation: General management and prognosis"</a>.)</p><p class="headingAnchor" id="H22"><span class="h4">Stress testing</span><span class="headingEndMark"> — </span>A stress test, usually with exercise, is typically performed after STEMI to detect residual ischemia. Stress testing also permits assessment of the exercise capacity needed for the cardiac rehabilitation exercise prescription and can, in some patients, identify arrhythmias. While the prognostic value of stress testing has declined in the reperfusion era, such an assessment is standard practice in the United States and required of patients referred to a cardiac rehabilitation program. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction", section on 'Stress testing'</a>.)</p><p>Predischarge stress testing to detect residual ischemia is generally not performed in patients who have undergone percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery and have been fully revascularized (eg, single vessel disease and successful PCI). Such patients often undergo exercise testing a few weeks or more after discharge as part of a cardiac rehabilitation program or for activity counseling.</p><p>Patients who have undergone partial revascularization or no revascularization, in contrast, are candidates for low level predischarge stress testing, which appears to be safe if:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient has undergone in-hospital cardiac rehabilitation</p><p class="bulletIndent1"><span class="glyph">●</span>There have not been symptoms of HF or recurrent angina</p><p class="bulletIndent1"><span class="glyph">●</span>The electrocardiogram (ECG) has been stable for 48 to 72 hours prior to the exercise test</p><p></p><p>Stress testing should not be performed in patients with unstable postinfarction angina, decompensated HF, or life-threatening cardiac arrhythmias.</p><p>The appropriate stress protocol varies with physician preferences, patient characteristics, and local laboratory expertise. This is discussed in detail separately.</p><p>Accurate interpretation cannot be achieved in patients with baseline ECG abnormalities such as left bundle branch block, LV hypertrophy with ST-T wave changes, ventricular preexcitation, or ventricular pacing. In such patients, either exercise echocardiography or exercise radionuclide myocardial perfusion imaging can be performed. Pharmacologic stress is required in patients who cannot exercise, although such modalities provide less information than exercise testing because they are not able to assess functional capacity  (<a class="graphic graphic_algorithm graphicRef87155" href="/z/d/graphic/87155.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1502.html" rel="external">"Selecting the optimal cardiac stress test"</a>.)</p><p>For patients with symptomatic ischemia on post-infarct stress testing, we suggest the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary angiography followed by revascularization if appropriate is performed in patients with noninvasive evidence suggesting a moderate to large amount of myocardium at risk. Examples include ischemia during stage I or II of the Bruce protocol, a hypotensive blood pressure response or symptoms of pulmonary congestion, more than 2 mm of ST segment depression, or imaging studies suggesting involvement of either a large portion of the anterior wall or showing multiple areas of ischemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with only mild ischemia can be continued on medical therapy alone but patient preference may be important.</p><p></p><p>The management of silent ischemia detected on stress testing is similar and discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1488.html" rel="external">"Silent myocardial ischemia: Epidemiology, diagnosis, treatment, and prognosis", section on 'Revascularization'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Chronic anticoagulation</span><span class="headingEndMark"> — </span>There is some evidence that initiating <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> therapy following STEMI can reduce reinfarction and cerebrovascular accidents and may reduce mortality following acute MI. The discussion of the indications for chronic anticoagulation after MI is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/101.html" rel="external">"Acute coronary syndrome: Oral anticoagulation in medically treated patients"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Ventricular arrhythmias</span><span class="headingEndMark"> — </span>The role of implantable cardioverter defibrillators after MI is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p>The management of late arrhythmias is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features", section on 'Late arrhythmias'</a>.)</p><p class="headingAnchor" id="H427106064"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>We recommend influenza and pneumococcal vaccination as part of a comprehensive secondary prevention program in adults with coronary and other atherosclerotic vascular diseases. If indicated, we suggest vaccination for these during hospitalization for an acute coronary syndrome. (See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Return to activities</span><span class="headingEndMark"> — </span>It is important that patients be counseled about returning to prior activities. The majority of patients who remain asymptomatic after an uncomplicated acute MI can probably return to prior nonphysical activities, including work, safely within two weeks, although few data are available.</p><p class="bulletIndent1"><span class="glyph">●</span>Daily physical activity, such as walking, should be encouraged; the intensity of physical activity can be increased according to the cardiac rehabilitation plan.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When sexual activity can be safely resumed is dependent upon a number of factors including whether or not the patient has been revascularized and, if not, if there is ischemia on stress testing  (<a class="graphic graphic_table graphicRef71511" href="/z/d/graphic/71511.html" rel="external">table 1</a>). An important caveat is that phosphodiesterase-5 inhibitors (<a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="10172" href="/z/d/drug information/10172.html" rel="external">vardenafil</a>, and <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>) cannot be taken within 24 to 48 hours of a nitrate. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1541.html" rel="external">"Sexual activity in patients with cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Driving can begin a week after discharge if the patient is judged to be in compliance with individual state laws.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since commercial aircrafts are pressurized to 7500 to 8000 feet, air travel should be undertaken only by stable patients (without a fear of flying) within the first two weeks and then only as long as they travel with companions, carry sublingual <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a>, and request airport transportation to avoid rushing. (See  <a class="medical medical_review" href="/z/d/html/1543.html" rel="external">"Approach to patients with heart disease who wish to travel by air or to high altitude", section on 'Air travel'</a>.)</p><p></p><p>For patients with a complicated MI, return to usual activities should be delayed by two to three weeks.</p><p class="headingAnchor" id="H27"><span class="h1">DISCHARGE MEDICATIONS</span><span class="headingEndMark"> — </span>Appropriate medical therapy can reduce the risk of subsequent ischemic events and mortality in patients who have had an acute MI. In addition to the interventions discussed in this section, beta blockers, statins, nitrates, and calcium channel blockers may be useful long term and are discussed above. (See <a class="local">'Further medical therapy'</a> above.)</p><p>Medications upon discharge from the hospital should include those important for risk reduction, including antiplatelet drugs, a beta blocker, a statin, and possibly an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB).</p><p class="headingAnchor" id="H28"><span class="h2">Antiplatelet drugs</span><span class="headingEndMark"> — </span>In the absence of an absolute contraindication, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is recommended indefinitely in all patients who have had an acute MI. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p>Treatment with a P2Y<sub>12</sub> receptor blocker is indicated in all patients after acute STEMI for at least one year, regardless of the reperfusion strategy. The specific recommendations for the duration of therapy after MI or stent placement are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Summary and recommendations'</a>.)</p><p class="headingAnchor" id="H29"><span class="h2">Angiotensin inhibition</span><span class="headingEndMark"> — </span>We start an ACE inhibitor in all STEMI patients prior to discharge. ACE inhibitors lead to improved 30-day mortality after acute STEMI, particularly in patients with an anterior infarct or reduced LV function, diabetes, or stable chronic kidney disease. An ARB is an alternative for patients unable to tolerate an ACE inhibitor (usually due to cough). (See  <a class="medical medical_review" href="/z/d/html/74.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use"</a>.)</p><p class="headingAnchor" id="H30"><span class="h2">Aldosterone antagonists</span><span class="headingEndMark"> — </span>For patients with STEMI who are receiving an ACE inhibitor and a beta blocker, and who have a LVEF less than or equal to 40 percent and either HF or diabetes, we prescribe a mineralocorticoid receptor antagonist, also referred to as an aldosterone blocker or antagonist [<a href="#rid3">3,4</a>]. Therapy should be begun before discharge, since a mortality benefit is seen within 30 days [<a href="#rid28">28</a>]. The serum potassium should be monitored closely during treatment. Although uncommon, life-threatening hyperkalemia can occur due to the combination of aldosterone inhibition, reduced aldosterone secretion associated with ACE inhibitor therapy, and a progressive decline in renal perfusion induced due to HF. Older adult patients with renal insufficiency are at greatest risk. The use of aldosterone antagonists is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a>.)</p><p>Although a 2018 meta-analysis found benefit to the addition of aldosterone antagonist in patients with STEMI without HF and with an ejection of more than 40 percent, we believe significant limitations to this study prevent us from recommending this therapy for these patients [<a href="#rid29">29,30</a>].</p><p class="headingAnchor" id="H31"><span class="h1">RISK FACTOR MODIFICATION</span><span class="headingEndMark"> — </span>Risk factor modification using behavioral/lifestyle changes such as dietary modification, increase in activity level, and smoking cessation are associated with better outcomes after acute coronary syndromes (ACS). Patient education should be given at the time of discharge and referral to a cardiac rehabilitation program should be made. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Lifestyle modifications'</a> and <a class="local">'Cardiac rehabilitation'</a> below.)</p><p class="headingAnchor" id="H32"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>Smoking cessation reduces the risk of recurrent MI. In one study of 564 postinfarction patients, for example, the risk of recurrent infarction fell by 50 percent within one year of smoking cessation and normalized to that of nonsmokers within two years [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1504.html" rel="external">"Cardiovascular risk of smoking and benefits of smoking cessation"</a>.)</p><p>We recommend education about smoking cessation during hospitalization and referral to a smoking cessation program or outpatient cardiac rehabilitation program. (See  <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults", section on 'Nicotine replacement therapy'</a>.)</p><p>However, the issue of whether <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement can be started during hospitalization has not been well studied. The safety of this approach was evaluated in a retrospective analysis of 194 smokers admitted with an ACS who received transdermal nicotine replacement therapy during their hospitalization [<a href="#rid32">32</a>]. Compared to a propensity-matched cohort, there was no difference in mortality at 7 and 30 days and at one year in patients started on nicotine replacement in-hospital.</p><p>We suggest cautious initiation of <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement during hospitalization for those patients with ACS in whom the benefits appear to outweigh the risks.</p><p class="headingAnchor" id="H33"><span class="h2">Long-term glycemic control</span><span class="headingEndMark"> — </span>We recommend a goal HbA1c of less than 7 percent, which is consistent with the general treatment goal for patients with type 2 diabetes. The supporting evidence and treatment goals are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Glycemic management'</a> and  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>Thiazolidinediones have been used in the treatment of patients with diabetes mellitus. A concern has been raised about the use of <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> in patients with coronary artery disease. (See  <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p class="headingAnchor" id="H34"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>Hypertension should be treated in patients who have had an MI. The optimal goal blood pressure and choice of antihypertensive drugs in such patients are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p class="headingAnchor" id="H35"><span class="h2">Diet</span><span class="headingEndMark"> — </span>Good dietary habits and use of a prudent diet can reduce the risk of coronary heart disease. (See  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults"</a>.)</p><p class="headingAnchor" id="H36"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>An increase in activity level in patients with established cardiovascular disease is associated with better outcomes. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a>.) An in-hospital assessment of exercise capacity should be made (phase I) and followed by transition into an outpatient phase II cardiac rehabilitation program. (See  <a class="medical medical_review" href="/z/d/html/1552.html" rel="external">"Cardiac rehabilitation: Indications, efficacy, and safety in patients with coronary heart disease"</a>.)</p><p class="headingAnchor" id="H37"><span class="h2">Stress management</span><span class="headingEndMark"> — </span>Psychosocial stress factors are associated with a poor prognosis after acute MI, and reducing emotional stress may improve outcomes. (See  <a class="medical medical_review" href="/z/d/html/4854.html" rel="external">"Psychosocial factors in acute coronary syndrome"</a>.)</p><p class="headingAnchor" id="H38"><span class="h2">Cardiac rehabilitation</span><span class="headingEndMark"> — </span>Multifactorial cardiac rehabilitation, which includes efforts to address all of the above issues, can produce significant long-term reductions in both total and cardiovascular mortality. All patients should be considered for referral to a cardiac rehabilitation facility. (See  <a class="medical medical_review" href="/z/d/html/1552.html" rel="external">"Cardiac rehabilitation: Indications, efficacy, and safety in patients with coronary heart disease"</a>.)</p><p class="headingAnchor" id="H402339514"><span class="h1">THERAPIES OF UNCLEAR BENEFIT</span></p><p class="headingAnchor" id="H1632985479"><span class="h2">Colchicine</span><span class="headingEndMark"> — </span>We do not routinely treat patients with acute MI with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>. Trials that evaluated the efficacy of colchicine arrived at different conclusions:</p><p class="bulletIndent1"><span class="glyph">●</span>In the COLCOT trial, 4745 patients with MI within 30 days and receiving optimal medical therapy were randomly assigned to <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> 0.5 mg daily or placebo [<a href="#rid33">33</a>]. Treatment began at a median of 14 days after ACS. The risk of the primary composite endpoint (death from cardiovascular causes, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina leading to coronary revascularization) was lower in the colchicine group (hazard ratio [HR] 0.77, 95% CI 0.61-0.96) after a median follow-up of nearly two years. This result was driven principally by lower risks of angina and stroke. Adverse events were generally similar in the two groups. A subsequent analysis of the impact of time-to-treatment initiation found that earlier (between days 0 and 3 after randomization) but not later initiation was associated with benefit [<a href="#rid34">34</a>]. Limitations of this study include the absence of improvement in hard endpoints such as cardiovascular death or MI and a relatively high discontinuation rate (about 18.5 percent in both groups).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Australian COPS trial randomly assigned 795 patients with ACS to <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> (0.5 mg twice daily for one month, then 0.5 mg daily for 11 months) or placebo during the index hospitalization [<a href="#rid35">35</a>]. Over 12 months of follow-up, there was no difference in the rate of the primary composite outcome (all-cause death, ACS, ischemia-driven urgent revascularization, and noncardioembolic ischemic stroke) in the two groups (24 and 38 events, respectively; 6.1 versus 9.5 percent; HR 0.65, 95% CI 0.38-1.09). There were more all-cause deaths in the colchicine group (eight versus one). The results of this trial need to be interpreted in view of its relatively small size.</p><p></p><p>The role of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> in chronic coronary disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Colchicine'</a>.)</p><p class="headingAnchor" id="H2340804742"><span class="h2">Hematopoietic stem cell therapy</span><span class="headingEndMark"> — </span>Hematopoietic stem cell therapy remains investigational; trials have not established the efficacy of stem cell therapies in patients with ACS [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H39"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Patients presenting with a non-ST-elevation MI have a lower in-hospital mortality than those with a STEMI, but a similar or perhaps worse long-term outcome. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1531.html" rel="external">"Prognosis after myocardial infarction"</a>.)</p><p class="headingAnchor" id="H4068896431"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H40"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15786.html" rel="external">"Patient education: Heart attack (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16327.html" rel="external">"Patient education: Heart attack recovery (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16334.html" rel="external">"Patient education: Medicines after a heart attack (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3447.html" rel="external">"Patient education: Heart attack (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3430.html" rel="external">"Patient education: Heart attack recovery (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H41"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute management</strong> – In patients with ST-elevation myocardial infarction (STEMI), early diagnostic and therapeutic interventions, such as antiplatelet therapy and emergency reperfusion, are associated with improved early outcomes. (See  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a> and  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonacute management</strong> – After the patient has been stabilized and early interventions have been carried out, the nonacute management of STEMI typically includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Beta blockers. (See <a class="local">'Oral beta blockers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Long-term dual antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and a P2Y<sub>12</sub> receptor blocker. (See <a class="local">'Antiplatelet drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Statins (high-intensity). (See <a class="local">'Statin therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aggressive management of recurrent myocardial ischemia or infarction. (See <a class="local">'Recurrent chest pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Angiotensin converting enzyme inhibitors in patients with diabetes, heart failure (HF), a left ventricular ejection fraction (LVEF) &lt;40 percent, and hypertension. (See <a class="local">'Angiotensin inhibition'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Risk factor modification of factors that include smoking, hypertension, diabetes, and dyslipidemia. (See <a class="local">'Risk factor modification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assessment of LV function. (See <a class="local">'Evaluation of left ventricular function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Long-term risk stratification. (See <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="headingAnchor" id="H867876138"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert S Rosenson, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495.</a></li><li><a class="nounderline abstract_t">Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711.</a></li><li><a class="nounderline abstract_t">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.</a></li><li><a class="nounderline abstract_t">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.</a></li><li><a class="nounderline abstract_t">Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39:119.</a></li><li><a class="nounderline abstract_t">Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.</a></li><li><a class="nounderline abstract_t">Langer A, Krucoff MW, Klootwijk P, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998; 31:783.</a></li><li><a class="nounderline abstract_t">Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317:581.</a></li><li><a class="nounderline abstract_t">Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990; 82:781.</a></li><li><a class="nounderline abstract_t">GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615.</a></li><li><a class="nounderline abstract_t">Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003; 42:7.</a></li><li><a class="nounderline abstract_t">Dönges K, Schiele R, Gitt A, et al. Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]). Am J Cardiol 2001; 87:1039.</a></li><li><a class="nounderline abstract_t">Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104:1229.</a></li><li><a class="nounderline abstract_t">Barbash GI, Birnbaum Y, Bogaerts K, et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. Circulation 2001; 103:954.</a></li><li><a class="nounderline abstract_t">Topol EJ, Burek K, O'Neill WW, et al. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med 1988; 318:1083.</a></li><li><a class="nounderline abstract_t">Mark DB, Sigmon K, Topol EJ, et al. Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry. Circulation 1991; 83:1186.</a></li><li><a class="nounderline abstract_t">Bogaty P, Dumont S, O'Hara GE, et al. Randomized trial of a noninvasive strategy to reduce hospital stay for patients with low-risk myocardial infarction. J Am Coll Cardiol 2001; 37:1289.</a></li><li><a class="nounderline abstract_t">Newby LK, Eisenstein EL, Califf RM, et al. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000; 342:749.</a></li><li><a class="nounderline abstract_t">Burns RJ, Gibbons RJ, Yi Q, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002; 39:30.</a></li><li><a class="nounderline abstract_t">Zaret BL, Wackers FJ, Terrin ML, et al. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. J Am Coll Cardiol 1995; 26:73.</a></li><li><a class="nounderline abstract_t">Sheehan FH, Doerr R, Schmidt WG, et al. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol 1988; 12:289.</a></li><li><a class="nounderline abstract_t">Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001; 134:451.</a></li><li><a class="nounderline abstract_t">Nijland F, Kamp O, Karreman AJ, et al. Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: a serial Doppler echocardiographic study. J Am Coll Cardiol 1997; 30:1618.</a></li><li><a class="nounderline abstract_t">Møller JE, Søndergaard E, Poulsen SH, Egstrup K. Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: a serial color M-mode Doppler echocardiographic study. J Am Coll Cardiol 2000; 36:1841.</a></li><li><a class="nounderline abstract_t">Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol 2002; 39:1450.</a></li><li><a class="nounderline abstract_t">Moller JE, Hillis GS, Oh JK, et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 2003; 107:2207.</a></li><li><a class="nounderline abstract_t">Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001; 103:1759.</a></li><li><a class="nounderline abstract_t">Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46:425.</a></li><li><a class="nounderline abstract_t">Dahal K, Hendrani A, Sharma SP, et al. Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis. JAMA Intern Med 2018; 178:913.</a></li><li><a class="nounderline abstract_t">Pitt B, Zannad F. Mineralocorticoid Receptor Antagonists in ST-Segment Elevation Myocardial Infarction. JAMA Intern Med 2018; 178:920.</a></li><li><a class="nounderline abstract_t">Wilhelmsson C, Vedin JA, Elmfeldt D, et al. Smoking and myocardial infarction. Lancet 1975; 1:415.</a></li><li><a class="nounderline abstract_t">Meine TJ, Patel MR, Washam JB, et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005; 95:976.</a></li><li><a class="nounderline abstract_t">Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 2019; 381:2497.</a></li><li><a class="nounderline abstract_t">Bouabdallaoui N, Tardif JC, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J 2020; 41:4092.</a></li><li><a class="nounderline abstract_t">Tong DC, Quinn S, Nasis A, et al. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation 2020; 142:1890.</a></li><li><a class="nounderline abstract_t">Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012; :CD006536.</a></li></ol></div><div id="topicVersionRevision">Topic 67 Version 76.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15007110" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Intensive versus moderate lipid lowering with statins after acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11277825" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247303" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247304" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886621" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9799205" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9525547" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2956516" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394002" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232430" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849652" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11348599" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11551872" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181469" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3281014" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2013140" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300437" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Randomized trial of a noninvasive strategy to reduce hospital stay for patients with low-risk myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10717009" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11755283" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797778" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3392324" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255520" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9385885" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: a serial Doppler echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11092654" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: a serial color M-mode Doppler echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11985906" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12695291" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Left atrial volume: a powerful predictor of survival after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11282907" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16053953" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29799995" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29799990" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mineralocorticoid Receptor Antagonists in ST-Segment Elevation Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/48609" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Smoking and myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15820167" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31733140" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860034" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32862667" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336818" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Stem cell treatment for acute myocardial infarction.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
